Drug Profile
Research programme: Parkinson's disease therapeutics - Proximagen/Upsher-Smith
Alternative Names: PRX-1; PRX-1235; PRX-2; PRX-5Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Proximagen Neuroscience
- Developer Boehringer Ingelheim; Proximagen; Upsher-Smith
- Class
- Mechanism of Action Nitric oxide synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuropathic pain; Parkinson's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in United Kingdom (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Parkinson's-disease in United Kingdom (PO)
- 14 Aug 2012 Proximagen has been acquired by Upsher-Smith